Hutzler D, Pevny I
Dermatologischen Klinik und Poliklinik, Universität Würzburg.
Derm Beruf Umwelt. 1988 May-Jun;36(3):86-90.
Evaluation of our standardized test results from 1972 to 1983 indicated Vioform allergies in 1.2% of all cases and Sterosan allergies in 1.1%. Our results are within the spectrum found in the literature for Vioform between 0.3 and 5.1% and for Sterosan between 0.3 and 3.7%. In the course of those 12 years we observed a growing tendency towards Vioform and Sterosan allergies on the basis of annual percentage figures. In the last year of our observation the frequency of Vioform and Sterosan allergies amounted to 1.7% each. We conclude, therefore, that inclusion of these two substances in the standard battery is justified. According to the pertinent literature, Sterosan and Vioform allergies are, on an average, 3 to 4 times more frequent in patients suffering from leg ulcers and/or chronic venous insufficiency than amongst eczema patients.
对我们1972年至1983年标准化测试结果的评估表明，所有病例中1.2%对碘仿过敏，1.1%对氯己定过敏。我们的结果在文献报道的碘仿过敏率0.3%至5.1%和氯己定过敏率0.3%至3.7%范围内。在这12年中，根据年度百分比数据，我们观察到对碘仿和氯己定过敏的趋势呈上升趋势。在我们观察的最后一年，碘仿和氯己定过敏的发生率均为1.7%。因此，我们得出结论，在标准测试组合中纳入这两种物质是合理的。根据相关文献，腿部溃疡和/或慢性静脉功能不全患者对氯己定和碘仿过敏的平均发生率比湿疹患者高3至4倍。
